Avatrombopag maleate
Registry-listed formulations
Avatrombopag maleate · chembl:CHEMBL2105758
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
2 source entries across 2 studies. This list may not include all unresolved or historical entries.
- Avatrombopag maleate 40 mgRegistry intervention
Linked study entry; product equivalence not established
View study and source - Doptelet PillRegistry intervention
Linked study entry; product equivalence not established
View study and source
Success Metrics
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
0
trials recruiting
3
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
Avatrombopaq In Patients With Cirrhosis
A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal
Clinical Trials (3)
Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
Avatrombopaq In Patients With Cirrhosis
A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal
All 3 trials loaded
Drug Details
- Intervention Type
- Drug
- Molecule Type
- Small molecule
- Total Trials
- 3